[Combined therapy of malignant tumors of the upper jaw and nasal cavity using pre- and post-operative radiation with metronidazol radiomodification].
Seventy-five patients with malignant tumors of the upper jaw and nasal cavity have received combination therapy. Administration of metronidasol (5-8 g/m2 body surface) in combination with large doses of preoperative radiation was shown to significantly improve 3-year total and recurrence-free survival-from 50 to 60% and 32 to 57%, respectively. As a result, no postoperative radiotherapy was required. Postoperative radiation treatment is indicated when means of radiosensibilization are not used. The use of radiomodifiers is mandatory in combination therapy of non-differentiated cell carcinoma, cylindroma, transitory-cell papilloma and non-epithelial neoplasms.
Andreev
V G
VG
Mardynskiĭ
I S
IS
Molotkova
N G
NG
Pankratov
V A
VA
Iglin
A V
AV
Romanko
I S
IS
Radzhanova
M U
MU
D017024:Chemotherapy, Adjuvant; D005500:Follow-Up Studies; D006801:Humans; D007573:Jaw Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008795:Metronidazole / Q000627:therapeutic use*; D009296:Nasal Cavity; D009669:Nose Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D011838:Radiation-Sensitizing Agents; D008795:Metronidazole